Biotech Stocks
The companies engineering the future of medicine.
Recent Biotech articles
Conexeu Sciences Is Coming After The Opportunity Created By GLP-1’s
Conexeu Sciences (NASDAQ: CNXU) has completed their preclinical study evaluating their proprietary CXU platform as a potential tissue restoration solution.
Christian Angermayer Leads $50 Million Round Into Enhanced Group
Enhanced Group (NYSE: ENHA) has successfully raised $50M USD in a new equity financing round at $3.89 per share.
Conexeu Sciences Is Preparing For Their First FDA Submission
Conexeu Sciences (NASDAQ: CNXU) has publicly stated they have begun scaling up their manufacturing and standardized formulation methods for Ten Minute Tissue.
Conexeu Sciences Starts Preclinical Development Program At Wake Forest University
Conexeu Sciences (NASDAQ: CNXU) has launched a preclinical development program for their 3D printed bioregenerative breast matrix at the Wake Forest Institute.
Regenerative Tissue Platform Company Conexeu Sciences Makes Nasdaq Debut
Regenerative tissue platform company Conexeu Sciences (NASDAQ: CNXU) has successfully completed a direct listing and begun trading on the Nasdaq.
Blackstone Raises Largest Private Fund Ever For Life Sciences
Blackstone (NYSE: BX) has successfully raised $6.3B USD for their Blackstone Life Sciences VI fund, making it the largest ever of its kind.
Chamath's Breast Cancer Company Wins FDA Approval
Perimeter Medical Imaging (TSXV: PINK) has received premarket approval from the United States Food and Drug Administration for their AI enabled imaging device.
Eli Lilly Is Stockpiling Weight Loss Pills
Eli Lilly (NYSE: LLY) has accumulated $1.5B USD of pre-launch inventory of their weight loss pill orforglipron according to new filings.
The Public Company Partnering Up With AMD On Drug Discovery
MindWalk Holdings (NASDAQ: HYFT) has partnered with AMD to leverage their technology to run large biology models for potential breakthroughs in drug discovery.
Eli Lilly And Nvidia Form New Drug Discovery Partnership
Nvidia (NASDAQ: NVDA) and Eli Lilly (NYSE: LLY) have formed a partnership focused on using artificial intelligence for developing new drugs and therapeutics.
The First Ever GLP-1 Pill Is Coming To The USA
Novo Nordisk (NYSE: NVO) has been granted regulatory approval from the United States Food and Drug Administration for their Wegovy GLP-1 pill for weight loss.
Pfizer Is Paying Billions For A GLP-1 Drug Development Company
Pfizer (NYSE: PFE) has entered into an amended merger agreement to acquire GLP-1 drug developer Metsera (NASDAQ: MTSR) in an all cash deal worth up to $10B USD.
Companies in Biotech
10x Genomics pioneers single-cell and spatial biology solutions, enabling researchers to analyze complex biological systems and drive breakthroughs in health science.
AbCellera is a biotechnology company specializing in antibody discovery and development, partnering with leading pharmaceutical firms to create innovative therapies.
AbbVie is a global biopharmaceutical company focused on therapies in immunology, oncology, neuroscience, and other specialized areas.
Amgen is a global pioneer in biotechnology, creating innovative therapies that address serious illnesses and improve global health outcomes.
Atossa Therapeutics develops targeted cancer therapies, focusing on innovative breast cancer treatments, advancing precision oncology, and meeting critical patient needs.
Beam Therapeutics is a biotechnology company pioneering precision genetic medicines through base editing to treat serious diseases.
BioAge Labs develops therapies targeting metabolic aging, focusing on obesity treatments like azelaprag to enhance healthspan.
Bionomics develops novel ion channel modulators for treating serious central nervous system disorders like anxiety and PTSD.
CRISPR Therapeutics develops transformative gene-based medicines using CRISPR/Cas9 technology, targeting serious diseases like sickle cell disease and cancer.
Clover Health offers Medicare Advantage plans powered by its Clover Assistant platform, delivering affordable, data-driven, and personalized healthcare solutions.
Conexeu develops collagen-based regenerative medicine and tissue scaffold technologies for wound care, reconstructive surgery, medical aesthetics, and tissue engineering.
Dexcom (NASDAQ: DXCM) leads in continuous glucose monitoring (CGM) technology, offering innovative solutions like the G6 and G7 systems for diabetes management worldwide.
Eli Lilly and Company innovates medicines to improve lives globally, with a focus on diabetes, oncology, and neuroscience.
Emergent BioSolutions develops vaccines, therapeutics, and biodefense solutions to address public health threats, serving governments and healthcare providers globally.
Enhanced Group operates sports competitions, telehealth services, and performance health platforms focused on human performance, recovery, longevity, and consumer wellness.
Ginkgo Bioworks engineers custom organisms for applications across industries, utilizing advanced automation and software to scale biological design.
HeartFlow delivers AI-powered, non-invasive heart modeling from CCTA scans—enhancing diagnosis and treatment of coronary artery disease worldwide.
Hyperfine revolutionizes medical imaging with Swoop®, the first FDA-cleared portable MRI system, enabling rapid bedside brain imaging for better patient care.
Labcorp is a global life sciences and healthcare company providing diagnostics and drug development laboratory services worldwide.
Medirom is expanding digital wellness infrastructure in Japan through biometric partnerships and connected health technologies.
MIRA Pharmaceuticals develops novel oral ketamine and marijuana analogs to treat neurologic and neuropsychiatric disorders.
Metsera develops innovative long-acting oral and injectable therapies targeting obesity and metabolic diseases using proprietary peptide technology.
MindWalk AI provides AI-augmented antibody discovery and biotherapeutic research services integrating wet-lab and in silico platforms.
Modivcare delivers NEMT, personal care, and remote monitoring services, improving healthcare access and outcomes for millions through data-driven, supportive care solutions.
Nanox is revolutionizing medical imaging with its innovative digital X-ray technology and AI solutions, aiming to make imaging more accessible and affordable worldwide.
Natera specializes in advanced genetic testing, offering solutions in oncology, women's health, and organ health to deliver precise, personalized healthcare insights.
NewAmsterdam Pharma is developing oral therapies targeting cardiovascular and metabolic diseases driven by residual LDL cholesterol risk.
Global healthcare leader Novo Nordisk specializes in diabetes and obesity treatments, driving innovation to combat serious chronic diseases.
Pfizer Inc. advances a diversified pharmaceutical and vaccine portfolio while pursuing cost-discipline and strategic pipeline investments.
Prime Medicine is a biotechnology company pioneering Prime Editing technology to develop precise, one-time curative genetic therapies for a broad range of diseases.
ProKidney Corp. is a clinical-stage biotechnology company pioneering cell therapies to treat chronic kidney disease, aiming to preserve kidney function and delay dialysis.
Quantum-Si revolutionizes proteomics with the first Next-Generation Protein Sequencer™, enabling precise single-molecule protein sequencing for advanced research.
Recursion Pharmaceuticals integrates AI and automation to revolutionize drug discovery, aiming to decode biology and expedite the development of new therapies.
Roivant Sciences is a biopharmaceutical company that develops transformative medicines and technologies by building agile, focused companies called Vants.
Semler Scientific develops healthcare technology like QuantaFlo®, a device for early detection of peripheral arterial disease, enhancing clinical outcomes.
Sensus Healthcare provides non-invasive, cost-effective superficial radiation therapy (SRT) devices for treating non-melanoma skin cancers and keloids.
Telomir Pharmaceuticals develops TELOMIR-1, a small molecule aimed at lengthening telomeres to combat age-related inflammatory conditions and promote DNA integrity.
Tempus uses AI to advance precision medicine, offering diagnostics and data-driven insights to personalize patient care across oncology, cardiology, and more.
TransMedics Group, Inc. offers the Organ Care System (OCS), a medical device that preserves donor organs for transplantation, enhancing organ viability and patient outcomes.
Viking Therapeutics develops innovative therapies for metabolic and endocrine disorders, focusing on obesity and liver diseases.
electroCore offers non-invasive vagus nerve stimulation devices for treating neurological conditions, enhancing patient outcomes with innovative bioelectronic therapies.
enGene Holdings advances non-viral gene-therapy delivery platforms for treatment of urological cancers and other mucosal-tissue disorders.
Biotechnology is where science meets market opportunity. Gene therapies, mRNA platforms, and precision medicine are moving from labs to clinics. The companies that successfully navigate FDA approval processes can see valuations transform overnight.
The biotech sector operates on binary outcomes. Clinical trial results can send stocks soaring or crashing. But beneath the volatility lies genuine innovation. CRISPR-based therapies are treating previously incurable diseases. AI is accelerating drug discovery timelines. And the pandemic proved that novel platforms can scale to meet global demand.
The New Money tracks the biotech companies pushing therapeutic boundaries. Pipeline progress, regulatory milestones, partnership deals, and the financing rounds that signal which approaches the market believes will succeed. High risk, high conviction, high potential.
